Founded in 2001, Cell>Point is a privately held biopharmaceutical company that is developing and commercializing intra-nuclear molecular imaging and therapeutic compounds for imaging cancer, diabetes, and cardiovascular disease, and the treatment of solid tumor and certain blood borne cancers using platform technologies licensed from The University of Texas M.D. Anderson Cancer Center (“M.D. Anderson”), Houston, Texas.